TY - JOUR
T1 - Drug delivery to tumors of the central nervous system.
AU - Lesniak, M. S.
AU - Langer, R.
AU - Brem, H.
N1 - Funding Information:
The research presented in this work has been supported in part by the National Cooperative Drug Discovery Group (UO1-CA52857 and AI 47739) of the National Cancer Institute (NCI-NIH), Bethesda, MD. Dr. Lesniak is a neurosurgical fellow whose research is supported by a grant from the American Brain Tumor Association, Chicago, IL.
PY - 2001/5
Y1 - 2001/5
N2 - Contemporary treatment of malignant brain tumors has been hampered by problems with drug delivery to the tumor bed. Inherent boundaries of the central nervous system, such as the blood-brain barrier or the blood-cerebrospinal fluid barrier, and a general lack of response to many chemotherapeutic agents have led to alternative treatment modalities. In general, all these modalities have sought to either disrupt or bypass the physiologic brain barriers and deliver the drug directly to the tumor. This article reviews past, as well as current, methods of drug delivery to tumors of the central nervous system. Special emphasis is placed on biodegradable polymers that can release chemotherapeutic agents against malignant gliomas. A variety of other nonchemotherapeutic drugs, including antiangiogenesis and immunotherapeutic agents, are presented in the context of new polymer technology. Finally, future directions in drug delivery are discussed with an overview on new advances in emerging biotechnology.
AB - Contemporary treatment of malignant brain tumors has been hampered by problems with drug delivery to the tumor bed. Inherent boundaries of the central nervous system, such as the blood-brain barrier or the blood-cerebrospinal fluid barrier, and a general lack of response to many chemotherapeutic agents have led to alternative treatment modalities. In general, all these modalities have sought to either disrupt or bypass the physiologic brain barriers and deliver the drug directly to the tumor. This article reviews past, as well as current, methods of drug delivery to tumors of the central nervous system. Special emphasis is placed on biodegradable polymers that can release chemotherapeutic agents against malignant gliomas. A variety of other nonchemotherapeutic drugs, including antiangiogenesis and immunotherapeutic agents, are presented in the context of new polymer technology. Finally, future directions in drug delivery are discussed with an overview on new advances in emerging biotechnology.
UR - http://www.scopus.com/inward/record.url?scp=0035352779&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035352779&partnerID=8YFLogxK
U2 - 10.1007/s11910-001-0020-z
DO - 10.1007/s11910-001-0020-z
M3 - Review article
C2 - 11898520
AN - SCOPUS:0035352779
SN - 1528-4042
VL - 1
SP - 210
EP - 216
JO - Current neurology and neuroscience reports
JF - Current neurology and neuroscience reports
IS - 3
ER -